Design and selection of medicaments that modulate the function and activity of interleukin 13

A technology selected from and equivalent to, applied in the direction of interleukin, drug combination, molecular design, etc., can solve problems such as chemical obstacles of carbohydrate building blocks
CN101970052AInactive Publication Date: 2011-02-09格莱坎生物科学股份有限公司
1 Cites 2 Cited by

Patent Information

Authority / Receiving Office
CN · China
Current Assignee / Owner
格莱坎生物科学股份有限公司
Publication Date
2011-02-09
Estimated Expiration
Not applicable · inactive patent

Smart Images

  • Figure 1
    Figure 1
  • Figure 2
    Figure 2
  • Figure 3
    Figure 3
Patent Text Reader

Abstract

The present invention relates generally to the field of medicaments in the form of therapeutic molecules including inflammatory modulators and their design and selection. More specifically, the present invention relates to a target site on Interleukin 13 (IL- 13) by which a GAG molecule or polyanionic glycoconjugate or anionic polysaccharide modulates IL-13 activity or function, said target site selected from the list consisting of amino acids located in the AB loops and / or helix D of human IL- 13 or its homolog or derivative, and the use of said IL- 13 target site to design a medicament for modulating physiological processes. Therapeutic and prophylactic compositions comprising the designed medicaments are also contemplated.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] Date of Application

[0002] This application is related to and claims priority to Australian Provisional Patent Application No. 2007907059, filed 21 December 2007, the entire contents of which are hereby incorporated by reference. technical field

[0003] In general, the present invention relates to the field of therapeutic molecular forms of drugs, including modulators of inflammation, and their design and selection. Therapeutic and prophylactic compositions comprising the drug are also contemplated. Background technique

[0004] Details of the author's bibliography of the publications mentioned in this specification are assembled at the end of the description.

[0005] The reference to any prior art in this specification is not and should not be considered as an acknowledgment or any form of suggestion that the prior art constitutes part of the general general knowledge of any country.

[0006] The design and selection of therapeutic molecules with a high degree ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More